Charles River Laboratories Intl. Inc vs Vanguard Value Index Fund ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $228.92 (market cap $11.14B), while Vanguard Value Index Fund ETF trades at $218.2. Which is the better fit depends on your goals.
| CRL | VTV | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | — |
52-Week High | $233.60 | $220.51 |
52-Week Low | $145.57 | $175.51 |
Enterprise Value | $14.00B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
VTV trades at $219.36, up 0.07% with a bullish technical outlook supported by moving averages and near-term resistance at $220. The ETF benefits from investor rotation into value stocks amid AI sector volatility, offering diversification with low tech exposure and a recent dividend declaration. It has gained 16% year-to-date, reflecting strong momentum in large-cap value equities.
The outlook remains positive as value stocks attract flows away from stretched growth valuations, though Fed policy and inflation risks could pressure returns. VTV's low expense ratio and defensive tilt provide stability, but macroeconomic shifts pose headwinds for continued outperformance.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →